PTGS2 and breast cancer: Similiar results were obtained when dividing the samples according to the data by Ristimaki et al. [34] reporting that 37% of breast cancers overexpress COX-2 (55.0% ± 10.9%, nlow = 17, nhigh = 12, P = 0.09).